Findings on Drug Development Reported by Investigators at York University (The Interdependent Influence of Lobbying and Intellectual Capital On New Drug Development)
Findings on Drug Development Reported by Investigators at York University (The Interdependent Influence of Lobbying and Intellectual Capital On New Drug Development)
Prof. Vareska van der Vrande, Dr Patricia Klopf, and the Research Software Engineering and Consulting (RSEC) team at RSM are listed as funders for this article on pharmaceutical firms' resource allocation decision toward lobbying and other non-market activities, and their their new drug launches.
The research is published in an Elsevier publication Research Policy, 2024;53(2).
Information for this cutting came from https://www.newsrx.com/NewsRxWebsite/
Participants
Vareska van de Vrande
Role: Faculty
Reference type: Co-written by
Patricia Klopf
Role: Faculty
Reference type: Co-written by
Media Outlets
NewsRX Drugs and Therapies (Online)
RSM uses cookies to measure website statistics, enable social media sharing and for marketing purposes.
By clicking accept cookies or by continuing to use this website, you are giving consent for us to set cookies when visiting this website.
See our cookie policy for more information about cookies and how to adjust your cookie settings.